Testing treatment to clear silent malaria germs in communities
Part of Infections clinical trials.
This Phase 2 trial studies a medicine to eliminate “silent” malaria parasites that can live in the community even when people feel well. It may help Rwanda move faster toward malaria elimination by reducing these hidden reservoirs and transmission.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18–65 years old (or be 5+ if you’re an “index case” for a household survey).
- You must have evidence of malaria parasites without symptoms, either in the community or after finishing standard malaria treatment.
- You need to be staying in Rwanda for at least the next month (if you are not a Rwandan resident).
- You cannot be using any other malaria medicine for prevention or treatment while in the study.
- You must not be pregnant.
- You should not have a known allergy to any ingredient in the study treatment, and you should not have joined another malaria drug/device study within the last 14 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new experimental antimalarial drug (GSK3772701) to see if it can safely and effectively treat uncomplicated malaria caused by P. falciparum parasites. You would receive the study drug by mouth and be monitored closely with blood tests and heart rhythm checks.
This study tests a new malaria vaccine in healthy adults. You will receive the vaccine and then be exposed to the malaria parasite in a controlled setting to check if the vaccine protects you.
This study tests a new long-acting malaria prevention injection (MMV371) in healthy adults and adolescents in Rwanda. Researchers will monitor how safe it is and how your body processes it over 24 weeks.
This trial tests a new combination of experimental malaria vaccines to see if they are safe and help protect against malaria. It includes both adults and young children in malaria-affected areas.
This trial tests if giving two malaria medicines together (dihydroartemisinin piperaquine and primaquine) to everyone in a community can help reduce malaria. It is for people living in high-risk areas in eastern Ghana.
This trial tests a new malaria drug (MMV055), alone or with another drug (MMV371), to see if it is safe and how the body processes it. It is for healthy people who want to help find new malaria treatments.
Hear when a new Malaria Falciparum trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.